Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer

21 Oct 2023

Abstract excerpt

BACKGROUND: -mutant medullary thyroid cancer in a phase 1-2 trial, but its efficacy as compared with approved multikinase inhibitors is unclear. METHODS: We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Thyroid and Parathyroid Surgery
Share to Thyroid Cancer Diagnosis and Treatment
Share to Thyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37870969
DOI: 10.1056/nejmoa2309719

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid CancerPMID 37870969Read ↗

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Selpercatinib in the treatment of thyroid cancer.Semantic proximity Read ↗

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.Semantic proximity Read ↗

Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.Semantic proximity Read ↗

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.Semantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectivesSemantic proximity Read ↗

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectivesSemantic proximity Read ↗

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.Semantic proximity Read ↗

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.